Alisertib: a new option for acute myeloid leukaemia
Mené sur 39 patients atteints d'une leucémie myéloïde aiguë à haut risque de récidive, cet essai de phase II évalue l'efficacité, du point de vue de la proportion de patients obtenant une rémission complète, et la toxicité d'un traitement d'induction de première ligne combinant une chimiothérapie (cytarabine et idarubicine) et l'alisertib (durée médiane de suivi : 13,7 mois)
Acute myeloid leukaemia is an aggressive disease with poor prognosis, particularly for certain high-risk subgroups. Current standard treatment includes remission induction chemotherapy, typically consisting of cytarabine combined with an anthracycline, an approach that has remained unchanged for more than 30 years. The clinical outcomes of high-risk patients continues to be unsatisfactory. However, the treatment for adults with acute myeloid leukaemia is currently undergoing rapid changes. The past decade has seen rapid growth in trials investigating targeted drugs, which tend to be combined with either the 7 + 3 chemotherapy backbone or low-intensity therapies. The US Food and Drug Administration and the European Medicines Agency have recently approved mutation-specific targeted agents, including FLT3 and IDH inhibitors, as well as novel agents such as the antibody-drug conjugate gemtuzumab ozogamicin, the BCL-2 inhibitor venetoclax, and the SMO inhibitor glasdegib.
The Lancet Haematology , commentaire, 2018